bluebird bioBLUE
BLUE
About: bluebird bio Inc is a biotechnology company engaged in researching, developing, and commercializing potentially curative gene therapies for severe genetic diseases based on its proprietary lentiviral vector (LVV) gene addition platform. The Company operates in a single segment, focusing on researching, developing, and commercializing potentially transformative gene therapies for severe genetic diseases.
Employees: 375
0
Funds holding %
of 7,419 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
731% more call options, than puts
Call options by funds: $40.7M | Put options by funds: $4.89M
2.83% less ownership
Funds ownership: 32.16% [Q3] → 29.33% (-2.83%) [Q4]
28% less capital invested
Capital invested by funds: $32.7M [Q3] → $23.7M (-$9M) [Q4]
42% less funds holding
Funds holding: 137 [Q3] → 80 (-57) [Q4]
77% less first-time investments, than exits
New positions opened: 16 | Existing positions closed: 71
95% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 61
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$5
22%
upside
Avg. target
$6.50
59%
upside
High target
$8
96%
upside
2 analyst ratings
1 positive
50%
1 neutral
50%
0 negative
0%
Barclays Gena Wang 7% 1-year accuracy 2 / 28 met price target | 96%upside $8 | Overweight Maintained | 31 Mar 2025 |
Wells Fargo Yanan Zhu 13% 1-year accuracy 2 / 16 met price target | 22%upside $5 | Equal-Weight Maintained | 24 Feb 2025 |
Financial journalist opinion
Based on 6 articles about BLUE published over the past 30 days
Neutral
Business Wire
1 week ago
bluebird bio confirms that Ayrmid, Ltd. has not delivered a binding offer or obtained necessary financing despite extensive engagement
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird” or “the Company”) today announced that after three weeks of engagement, including a timeline extension, Ayrmid Ltd. (“Ayrmid”) has not submitted a binding proposal to acquire bluebird and has not obtained necessary financing. In consultation with its financial and legal advisors, the bluebird Board of Directors (the “Board”) reaffirms its recommendation in support of the transaction with Carlyle and SK Capital and.
Positive
Benzinga
3 weeks ago
Gene Therapy-Focused Bluebird Bio Receives Rival Takeover Offer, Stock Jumps
Bluebird Bio, Inc. BLUE received an unsolicited, non-binding written proposal from Ayrmid Ltd. on Friday.
Positive
Reuters
3 weeks ago
Bluebird bio receives non-binding bid for up to $110.5 million
Gene therapy maker bluebird bio said on Friday it had received a non-binding offer from peer Ayrmid for up to $110.5 million, sending its shares up 9.8% at $4.40 in extended trading.
Positive
Market Watch
3 weeks ago
Bluebird Bio Reviewing Buyout Offer From Ayrmid for Up to $110.5 Million -- Update
Bluebird Bio has received a competing bid from Ayrmid to buy the cash-strapped gene-therapy company in a deal potentially valued at up to $110.5 million.
Neutral
Business Wire
3 weeks ago
bluebird bio Confirms Receipt of an Unsolicited Non-Binding Proposal from Ayrmid
SOMERVILLE, Mass.--(BUSINESS WIRE)--bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird”) today confirmed it has received an unsolicited non-binding written proposal (the “Ayrmid Proposal”) from Ayrmid Ltd (“Ayrmid”) to acquire bluebird for an upfront cash payment of $4.50 per share and a one-time contingent value right of $6.84 per share payable upon achievement of a net sales milestone. As previously announced on February 21, 2025, bluebird entered into a definitive agreement (the “Merger Agreement”.
Negative
Zacks Investment Research
3 weeks ago
Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates
Bluebird Bio (BLUE) came out with a quarterly loss of $23.74 per share versus the Zacks Consensus Estimate of a loss of $6.60. This compares to loss of $15.60 per share a year ago.
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Bluebird Bio, Inc. - BLUE
NEW YORK CITY, NY / ACCESS Newswire / March 19, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Neutral
PRNewsWire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK , March 17, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ: BLUE).
Neutral
Accesswire
1 month ago
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, inc. - BLUE
NEW YORK, NY / ACCESS Newswire / March 15, 2025 / Pomerantz LLP is investigating claims on behalf of investors of bluebird bio, inc. ("bluebird" or the "Company") (NASDAQ:BLUE).
Neutral
Business Wire
1 month ago
BLUEBIRD BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of bluebird bio, Inc. - BLUE
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of bluebird bio, Inc. (NasdaqGS: BLUE) to Carlyle Group and SK Capital Partners, LP. Under the terms of the agreement, bluebird shareholders will receive $3.00 per share in cash and a contingent value right per share, entitling the holder to a payment of $6.84 in cash per contingent value right if blue.
Charts implemented using Lightweight Charts™